Skip to content
OpenCapital
Get started

Coherus BioSciences CHRS Q1 2026 earnings

Reported May 11, 2026 · After market close

Revenue$12.3MMiss by $1.9M
EPS-$0.25Beat by $0.01
Revenue estimate$14.2M
EPS estimate-$0.26

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$14.4M
EPS estimate-$0.12

Versus estimates

Revenue

Q1 2026$12.3MMiss by $1.9M
Q4 2025$12.7MMiss by $1.2MQ3 2025$11.6MMiss by $2.5MQ2 2025$10.3MMiss by $1.7MQ1 2025$7.6MMiss by $53.4MQ4 2024$54.1MMiss by $5.9M

Diluted EPS

Q1 2026-$0.25Beat by $0.01
Q4 2025-$0.34Beat by $0.02Q3 2025-$0.33Miss by $0.01Q2 2025-$0.34Miss by $0.03Q1 2025-$0.35Miss by $0.04Q4 2024-$0.28Miss by $0.18

Ask the moment Coherus BioSciences reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Coherus BioSciences report Q1 2026 earnings?
Coherus BioSciences (CHRS) reported Q1 2026 earnings on May 11, 2026 after market close.
What were Coherus BioSciences's Q1 2026 revenue and EPS?
Coherus BioSciences reported revenue of $12.3M and eps of $-0.25 for Q1 2026.
Did Coherus BioSciences beat estimates in Q1 2026?
Revenue missed the consensus estimate of $14.2M by $1.9M. EPS beat the consensus estimate of $-0.26 by $0.01.
How did Coherus BioSciences's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 62.0% from $7.6M a year earlier and eps grew 28.6% from $-0.35.
Where can I find Coherus BioSciences's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-058666) and the 10-Q periodic report (0001104659-26-058703) directly on SEC EDGAR. The filing index links above go to sec.gov.